Physician profile
Daniel Bolet
NPI 1548562051
$18,520.91
in general payments reported to CMS, 2019-2025
27 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $6,316 · 2021: $9,587 · 2022: $387 · 2023: $435 · 2024: $337 · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $15,456.16 | 2020-2021 | |
| Shield Therapeutics INC | $763.43 | 2023-2025 | Accrufer |
| Daiichi Sankyo INC. | $525.37 | 2023-2025 | Injectafer |
| Hologic Sales and Service, LLC | $456.57 | 2020-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Myovant Sciences INC. | $306.43 | 2021-2022 | |
| Astellas Pharma US INC | $211.84 | 2022-2025 | Veozah |
| Abbvie INC. | $177.17 | 2021-2022 | |
| Becton, Dickinson and Company | $97.45 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.72 | 2019-2023 | |
| Pfizer INC. | $46.24 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $44.01 | 2023-2025 | Myfembree |
| Axonics, INC. | $43.62 | 2023 | Axonics |
| Evofem Biosciences, INC. | $42.12 | 2025 | Solosec, Phexx, Phexxi |
| Therapeuticsmd, INC. | $34.08 | 2019-2021 | |
| Boston Scientific Corporation | $30.58 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $26.48 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $25.23 | 2025 | |
| Coopersurgical, INC. | $22.89 | 2022 | |
| Meditrina | $21.06 | 2020 | |
| Agile Therapeutics, INC. | $19.00 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.55 | 2025 | Voquezna |
| Exeltis, USA INC. | $16.30 | 2022 | |
| Davol INC. | $15.09 | 2025 | Arista |
| Lupin INC. | $14.95 | 2019 | |
| Duchesnay USA Incorporated | $12.76 | 2019 | |
| Allergan, INC. | $12.74 | 2019 | |
| Millicent US INC | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bolet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.